| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||||
Total revenues | |||||||||||
219,750 | 74,908 | 89,912 | 47,159 | 41,097 | 50,561 | 47,167 | 66,725 | 82,757 | 100,041 | 100,533 | 96,163 |
Operating costs and expenses: | |||||||||||
Cost of goods sold | |||||||||||
25,062 | 1,802 | 0 | - | - | - | - | - | - | - | - | - |
Research and development | |||||||||||
655,114 | 505,420 | 390,635 | 382,392 | 276,495 | 190,249 | 112,957 | 86,569 | 99,295 | 106,384 | 108,730 | 96,883 |
Selling, general and administrative | |||||||||||
479,005 | 382,359 | 199,365 | 89,354 | 60,610 | 44,526 | 27,152 | 44,612 | 38,280 | 37,727 | 39,914 | 27,115 |
Total operating costs and expenses | |||||||||||
1,159,181 | 889,581 | 590,000 | 471,746 | 337,105 | 455,541 | 140,109 | 196,181 | 137,575 | 144,111 | 148,644 | 123,998 |
In-process research and development | |||||||||||
- | - | - | - | - | 220,766 | - | - | - | - | - | - |
Restructuring of Tekmira license agreement | |||||||||||
- | - | - | - | - | - | - | 65,000 | - | - | - | - |
Loss from operations | |||||||||||
-939,431 | -814,673 | -500,088 | -424,587 | -296,008 | -404,980 | -92,942 | -129,456 | -54,818 | -44,070 | -48,111 | -27,835 |
Other income: | |||||||||||
Equity in loss of joint venture (Regulus Therapeutics Inc.) | |||||||||||
- | - | - | - | - | - | - | -4,522 | -3,505 | -7,639 | -4,910 | -9,290 |
Gain on issuance of stock by Regulus Therapeutics Inc. | |||||||||||
- | - | - | - | - | - | - | 16,084 | - | 4,421 | - | - |
Interest income | |||||||||||
33,448 | 29,262 | 12,236 | 8,308 | 5,859 | 2,559 | 1,069 | 977 | 1,205 | 2,305 | 5,385 | 14,414 |
Interest expense | |||||||||||
- | - | - | - | - | - | - | - | - | - | - | 872 |
Other income | |||||||||||
11,308 | 4,173 | -3,022 | 6,171 | 76 | 1,817 | -47 | 331 | -531 | 1,982 | 628 | -1,947 |
Change in fair value of liability obligation | |||||||||||
9,422 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Gain on litigation settlement | |||||||||||
0 | 20,564 | 0 | - | - | - | - | - | - | - | - | - |
Total other income | |||||||||||
54,178 | 53,999 | 9,214 | 14,479 | 5,935 | 4,376 | 1,022 | 12,870 | -2,831 | 1,069 | 1,103 | 2,305 |
Loss before income taxes | |||||||||||
-885,253 | -760,674 | -490,874 | -410,108 | - | -400,604 | -91,920 | -116,586 | -57,649 | -43,001 | -47,008 | -25,530 |
Provision for income taxes | |||||||||||
900 | 823 | 0 | 0 | - | -40,209 | -2,695 | -10,572 | 0 | 514 | 582 | 719 |
Net loss | |||||||||||
-886,116 | -761,497 | -490,874 | -410,108 | -290,073 | -360,395 | -89,225 | -106,014 | -57,649 | -43,515 | -47,590 | -26,249 |
Net loss per common share - basic and diluted (in dollars per share) | |||||||||||
-8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 |
Weighted-average common shares used to compute basic and diluted net loss per common share (in shares) | |||||||||||
109,264 | 100,590 | 90,554 | 85,596 | 83,992 | 74,278 | 61,551 | 50,286 | 42,410 | 42,040 | 41,633 | 41,077 |
Statements of Comprehensive Loss | |||||||||||
Net loss | |||||||||||
-886,116 | -761,497 | -490,874 | -410,108 | -290,073 | -360,395 | -89,225 | -106,014 | -57,649 | -43,515 | -47,590 | -26,249 |
Unrealized gain on marketable debt securities | |||||||||||
558 | 1,220 | -2,886 | -30,833 | -44,394 | 31,127 | 4,055 | 15,827 | -879 | 27 | -349 | 833 |
Foreign currency translation | |||||||||||
-343 | 0 | 0 | - | - | - | - | - | - | -29 | -121 | 53 |
Defined benefit pension plans, net of tax | |||||||||||
3,520 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Reclassification adjustment for realized loss on marketable securities included in net loss | |||||||||||
0 | 0 | -1,894 | 6,977 | - | 2,081 | - | - | - | - | - | - |
Comprehensive loss | |||||||||||
-889,421 | -760,277 | -491,866 | -447,918 | -334,467 | -331,349 | -85,170 | -90,187 | -58,528 | -43,517 | -48,060 | -25,363 |
Research and development | |||||||||||
- | - | - | - | - | - | - | - | - | - | 11,415 | 9,575 |
General and administrative | |||||||||||
- | - | - | - | - | - | - | - | - | - | 8,312 | 6,807 |
Net product revenues | |||||||||||
Total revenues | |||||||||||
166,537 | 12,535 | 0 | - | - | - | - | - | - | - | - | - |
Net revenues from collaborations | |||||||||||
Total revenues | |||||||||||
53,213 | 62,373 | 89,912 | 47,159 | - | - | - | - | - | - | - | - |